## Company Leadership 

## Board of Directors 

Alan H. Auerbach Chairman, President and Chief Executive Officer Puma Biotechnology, Inc. 

Thomas R. Malley President Mossrock Capital, LLC 

Jay M. Moyes Chief Financial Officer (retired) Myriad Genetics, Inc. 

Troy E. Wilson, Ph.D., J.D. President and Chief Executive Officer Avidity NanoMedicines LLC President and Chief Executive Officer Wellspring Biosciences LLC 

## Corporate Officers 

Alan H. Auerbach Chairman, President and Chief Executive Officer 

Richard P. Bryce, MBChB, MRCGP, MFPM Senior Vice President, Clinical Research & Development 

Charles R. Eyler Senior Vice President, Finance and Administration, and Treasurer 

Richard B. Phillips, Ph.D. Senior Vice President, Regulatory Affairs, Quality Assurance and Pharmacovigilance 

Forward-Looking Statements 

## Stockholder Information 

## Corporate Headquarters 

Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles, CA 90024 424-248-6500 

## Investor Relations 

Securities analysts, investment professionals and stockholders should direct inquiries to Investor Relations at 424-248-6500 Ext. 2011 or ir@pumabiotechnology.com. 

For further information about Puma, please visit our website at www.pumabiotechnology.com. 

## Common Stock 

Puma’s common stock is listed on the New York Stock Exchange under the trading symbol “PBYI.” 

## Transfer Agent 

## Wells Fargo Shareowner Services SM 

Mail: P.O. Box 64854 St. Paul, MN 55164 

Courier: 1110 Centre Pointe Curve, Suite 101 Mendota Heights, MN 55120-4100 

Telephone: 800-468-9716 651-450-4064 

Website: www.shareowneronline.com 

## Annual Meeting 

The 2014 Annual Meeting of Stockholders will be held at 1:00 p.m. PDT on Tuesday, June 10, 2014, at the Luxe Sunset Boulevard Hotel 11461 Sunset Boulevard Los Angeles, CA 90049 

## Independent Registered Public Accounting Firm 

## PKF Certified Public Accountants, a Professional Corporation 

2020 Camino del Rio North, Suite 500 San Diego, CA 92108 

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi- ties Exchange Act of 1934, as amended, including statements regarding anticipated timing for the commencement and completion of various clinical trials and the announcement of data relative to these trials. These statements are often, but not always, made through the use of words or phrases such as “anticipates,” “expects,” “plans,” “believes,” “intends,” and similar words or phrases. Discussions containing these forward-looking statements may be found throughout this docu- ment, including the sections entitled “Item 1. Business” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. All forward-looking statements included in this document involve risks and uncertainties that could cause the Company’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Company’s dependence on PB272 (neratinib (oral)), which is its lead product candidate and is still under development and may never receive regula- tory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Company’s drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Company’s products; the Company’s reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Company’s dependence on licensed intellectual property; and the other risk fac- tors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which is included herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law. 

